Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Pfizer Upgraded To Overweight; Goldman Downgrades Kimco To Sell

|Includes: Cognizant Technology Solutions Corporation (CTSH), JNJ, KIM, LABL, PFE, SAIC, T, ZBH

Here are today's top Wall Street analyst ratings where finbox.io's unbiased fair value estimates support the recommendation.

Top Upgrades
  • Cantor Fitzgerald raised Cognizant Technology Solutions' (NASDAQ:CTSH) target price to $67 per share. Finbox.io's fair value estimate is slightly lower at $66 per share implying 18% upside.

  • Barclays upgraded Pfizer (NYSE:PFE) from Equal Weight to Overweight. Twelve valuation models suggest the stock is currently 15% undervalued.

  • Jefferies Group reiterated its Buy rating on AT&T (NYSE:T). Eleven valuation models imply a fair value of $45.50 per share representing 15% upside.

  • Citigroup upgraded Zimmer Biomet (NYSE:ZBH). The rating change is supported by the company's underlying fundamentals.

Top Downgrades
  • Citigroup downgraded Science Applications International (NYSE:SAIC). Shares are currently trading at a 24% premium.

  • KeyCorp downgraded Multi-Color Corp (NASDAQ:LABL) from Sector Weight to Underweight. Ten free cash flow models imply the stock is 20% overvalued.

  • Barclays downgraded Johnson & Johnson (NYSE:JNJ) from Overweight to Equal Weight. Fundamentals support the rating change.

  • Goldman Sachs downgraded Kimco Realty (NYSE:KIM) from Neutral to Sell. Eight valuation models support the rating and conclude a negative 14% margin of safety.